BioAdaptives Inc. (BDPT)
Las Vegas, NV, US
BioAdaptives, Inc. investigates, markets, and distributes natural plant, algal, and mushroom-based products and medical devices for humans and animals. It offers nutraceutical products, such as dietary supplements. The company offers Human Clinical trial; Zeranovia, a natural ingredient and uses proprietary methods of optimizing the availability of nutrients in foods and beverages; Lung Flute, a medical device; and Xcellara, PawPa, and MyndMed. The company was formerly known as APEX 8 Inc. and changed its name to BioAdaptives, Inc. in September 2013. The company was incorporated in 2013 and is based in Las Vegas, Nevada.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -18.18% | -18.18% | -29.96% | -40.00% | -59.09% | -59.09% | -85.25% | -90.00% | -99.79% | -99.97% | -99.40% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Packaged Foods: +4.4%+44.3% ★
-
EPS growth Packaged Foods: +14.6%-36.4% Q1'26: +57.8% (vs Q1'25)
-
FCF margin FCF growth · Packaged Foods: +15.9%-5,403.7% Q1'26: -1,538.6% (vs Q1'25)
-
EBIT margin Packaged Foods: +7.9%-8,135.6% Q1'26: -3,594.8% (vs Q1'25)
-
ROIC Packaged Foods: +7.0%— Q1'26: +45.2% (vs Q1'25)
-
Share dilution Packaged Foods: +0.0%+22.6% Q1'26: +32.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Packaged Foods: 0.19×-0.37× Q1'26: -0.58× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-01 | FRISSORA MARK P | Director | J-Other | A | Series D Convertible Preferred Stock | 4,808 | 0.00 | — | 71,554 | D | ↗ |
| 2026-04-01 | FRISSORA MARK P | Director | J-Other | A | Series D Convertible Preferred Stock | 4,386 | 0.00 | — | 66,746 | D | ↗ |
| 2026-03-01 | FRISSORA MARK P | Director | J-Other | A | Series D Convertible Preferred Stock | 2,578 | 0.00 | — | 62,360 | D | ↗ |
| 2026-02-01 | FRISSORA MARK P | Director | J-Other | A | Series D Convertible Preferred Stock | 2,565 | 0.00 | — | 59,779 | D | ↗ |
| 2026-01-01 | FRISSORA MARK P | Director | J-Other | A | Series D Convertible Preferred Stock | 2,286 | 0.00 | — | 57,217 | D | ↗ |
| 2025-12-01 | FRISSORA MARK P | Director | J-Other | A | Series D Convertible Preferred Stock | 2,025 | 0.00 | — | 54,931 | D | ↗ |
| 2025-11-01 | FRISSORA MARK P | Director | J-Other | A | Series D Convertible Preferred Stock | 1,382 | 0.00 | — | 52,906 | D | ↗ |
| 2025-10-01 | FRISSORA MARK P | Director | J-Other | A | Series D Convertible Preferred Stock | 1,517 | 0.00 | — | 51,524 | D | ↗ |
| 2025-09-01 | FRISSORA MARK P | Director | J-Other | A | Series D Convertible Preferred Stock | 1,506 | 0.00 | — | 50,007 | D | ↗ |
| 2025-08-01 | FRISSORA MARK P | Director | J-Other | A | Series D Convertible Preferred Stock | 1,307 | 0.00 | — | 48,501 | D | ↗ |
| 2025-07-15 | FRISSORA MARK P | Director | — | — | Series D Convertible Preferred Stock | 363,700 | 0.00 | — | 0 | D | ↗ |
| 2025-07-01 | FRISSORA MARK P | Director | J-Other | A | Series D Convertible Preferred Stock | 847 | 0.00 | — | 47,194 | D | ↗ |
| 2025-06-01 | FRISSORA MARK P | Director | J-Other | A | Series D Convertible Preferred Stock | 713 | 0.00 | — | 46,347 | D | ↗ |
| 2025-05-01 | FRISSORA MARK P | Director | J-Other | A | Series D Convertible Preferred Stock | 694 | 0.00 | — | 45,634 | D | ↗ |
| 2025-04-15 | FRISSORA MARK P | Director | A-Award | A | Series D Convertible Preferred Stock | 501 | 0.00 | — | 44,940 | D | ↗ |
| 2025-04-09 | FRISSORA MARK P | Director | P-Purchase | A | Series D Convertible Preferred Stock | 39,868 | 0.00 | — | 44,439 | D | ↗ |
| 2025-03-15 | FRISSORA MARK P | Director | A-Award | A | Series D Convertible Preferred Stock | 479 | 0.00 | — | 4,571 | D | ↗ |
| 2025-02-15 | FRISSORA MARK P | Director | A-Award | A | Series D Convertible Preferred Stock | 455 | 0.00 | — | 4,092 | D | ↗ |
| 2024-11-22 | Dissanayake Gimhana Sasanka | Director | P-Purchase | A | Common | 125,000 | 0.09 | 10.6K | 125,000 | D | ↗ |
| 2013-10-01 | FERRIS HOLDING INC. | 10% Owner | P-Purchase | A | Common Stock | 41,667 | 0.12 | 5.0K | 10,041,667 | — | ↗ |
| 2013-10-01 | EPLING BARRY | Director / 10% Owner | P-Purchase | A | Common Stock | 41,667 | 0.12 | 5.0K | 10,041,667 | — | ↗ |
| 2013-06-21 | FERRIS HOLDING INC. | 10% Owner | — | D | Common stock | 0 | 0.00 | — | 10,000,000 | — | ↗ |
| 2013-06-21 | EPLING GERALD | Director / Officer | — | D | Common stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2013-06-21 | EPLING BARRY | Director | — | I | Common stock | 0 | 0.00 | — | 10,000,000 | — | ↗ |
| 2013-06-21 | Chiang Richard | — | S-Sale | D | Common Stock | 10,000,000 | 0.00 | 40.0K | 0 | — | ↗ |
| 2013-05-03 | Chiang Richard | Director / Officer / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 10,000,000 | — | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| James Keener | Chief Executive Officer & Chairman | — | male |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BDPT
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
